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Abstract
Background and Aims: Crohn’s disease [CD] is a chronic inflammatory disease with unpredictable 
behaviour. More than half of CD patients eventually develop complications such as stenosis, for 
which they then require endoscopic dilatation or surgery, as no anti-fibrotic drugs are currently 
available. We aim to identify disease-modifying genes associated with fibrostenotic CD.
Methods: We performed a within-case analysis comparing ‘extreme phenotypes’ using the 
Immunochip and replication of the top single nucleotide polymorphisms [SNPs] with Agena 
Bioscience in two independent case-control cohorts totalling 322 cases with fibrostenotis [recurrent 
after surgery] and 619 cases with purely inflammatory CD.
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Results: Combined meta-analysis resulted in a genome-wide significant signal for SNP rs11861007 
[p  =  6.0910–11], located on chromosome 16, in lncRNA RP11-679B19.1, an lncRNA of unknown 
function, and close to exon 9 of the WWOX gene, which codes for WW domain-containing 
oxidoreductase. We analysed mRNA expression of TGF-β and downstream genes in ileocecal 
resection material from ten patients with and without the WWOX risk allele. Patients carrying the 
risk allele [A] showed enhanced colonic expression of TGF-β compared to patients homozygous for 
the wild-type [G] allele [p = 0.0079].
Conclusion: We have identified a variant in WWOX and in lncRNA RP11-679B19.1 as a disease-
modifying genetic variant associated with recurrent fibrostenotic CD and replicated this association 
in an independent cohort. WWOX can potentially play a crucial role in fibrostenosis in CD, being 
positioned at the crossroads of inflammation and fibrosis.
Key Words:  Crohn’s disease; fibrosis; genetics
1. Introduction
Crohn’s sisease [CD] is a chronic inflammatory bowel disease [IBD] 
with unpredictable disease behaviour; more than half of CD patients 
eventually develop complications such as fistulae and stenosis.1 
Patients with fibrosis-induced stenosis require endoscopic dilata-
tion or surgery, as no anti-fibrotic drugs are currently available. 
The estimated lifetime risk for surgery in CD patients is 70%, with 
fibrostenosis as the most common indication for surgery.2 Within 
18 months after surgery, the endoscopic recurrence rate of fibroste-
nosis is 40–60%.3
Fibrostenosis of the intestine is a result of chronic inflamma-
tion: the permanent scarring and the consequent luminal narrowing 
is induced by continuous events of injury and healing. Finally, the 
intestine is no longer able to restore the normal histological con-
figuration and excessive deposition of extracellular matrix prevails. 
This leads to thickening of the intestinal wall, which in turn leads to 
luminal stricturing, finally causing stenosis and obstruction.
Genetic studies of IBD have identified over 240 risk loci associ-
ated with disease development.4,5 A large genotype–phenotype asso-
ciation study was performed, including 34 819 IBD patients, which 
identified three loci [NOD2, MHC and MST1 3p21] associated with 
disease location.6 However, only a few risk variants are known that 
influence disease behaviour, such as SMAD3 with recurrent surgery 
in CD, MAGI1 with complicated structuring CD, and FOXO3, 
XACT and IGFBP1-3 with severe disease course in CD.7–10 Variants 
associated with disease onset seem not to be associated with disease 
behaviour, which suggests that the biological pathways that under-
lie disease behaviour are distinct from those that underlie disease 
onset.10 In this study, we aim to identify disease-modifying genes 
associated with the fibrostenotic phenotype in CD. This will help 
us gain insight into the biological mechanisms underlying intestinal 
fibrosis development, which might open new avenues for the treat-
ment of CD.
We performed a within-case analysis comparing ‘extreme phe-
notypes’, an approach that provides power to detect associations 
within disease cohorts that has previously been successfully adopted 
for other traits, including obesity.11,12 We used an immune-focused 
fine mapping chip [Immunochip] with 166 251 single nucleotide 
polymorphisms [SNPs], in two independent case-control cohorts 
totalling 322 individuals with multiple [two or more] resections due 
to confirmed ileal stenosis, which we used as cases, and which we 
compared to patients with 619 purely inflammatory CD [non-pene-
trating/non-fibrostenotic with disease duration > 5 years]. Following 
this approach, we identified and replicated a variant within lncRNA 
RP11-679B19.1 and in WWOX, as a disease-modifier, associated 
with recurrent fibrostenotic CD. We then studied the potential func-
tional consequences of this variant by studying resection material of 
CD patients carrying the risk allele.
2. Methods
2.1. Genetic analysis [cohort description, quality 
control and statistical analysis]
2.1.1. Subjects
The discovery cohort consisted of 521 Dutch CD patients, selected 
out of ~ 1500 Dutch CD patients. Selection was based on review-
ing the medical records of the total cohort of 1500 patients. We 
selected patients on extreme ends of the fibrostenotic phenotype: a 
case group and a control group. The case group consisted of 242 
patients with ‘recurrent fibrostenotic’ CD, which was defined as the 
need for multiple [two or more] resections due to confirmed ileal 
stenosis. The control group consisted of 279 patients with purely 
inflammatory disease behaviour CD [Montreal classification B113] 
defined as non-penetrating, non-fibrostenotic CD with a disease 
duration of > 5 years, without the need for any kind of surgery. All 
patients of the discovery cohort were also included in the IIBDGC 
core-phenotype study.6
For the replication phase, patients were selected from the 
Parelsnoer Institute database [http://www.parelsnoer.org/]. This 
database consists of 3394 IBD patients [CD: n  =  2118] collected 
from the IBD Centres in all eight University Medical Centres in the 
Netherlands. Patients already included in the discovery phase were 
excluded. Eighty CD patients with recurrent fibrostenotic disease 
and 340 patients with purely inflammatory disease were selected 
with similar criteria. While the phenotypes of the discovery cohort 
could be checked against the patients’ medical charts, regulations 
prevented us from doing the same with the replication cohort. Hence, 
the replication cohort might have some non-cases and/or non-con-
trols admixed. All patients were of Central European descent.
2.2.2. Discovery phase
2.1.2.1. Immunochip genotyping
In the discovery phase of the study we used genotype data of ~1500 
CD patients described by Jostins et al.14 In brief, DNA was extracted 
from whole blood. An Illumina Immunochip was used to genotype 
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the DNA samples. The Immunochip is a custom Illumina Infinium 
immune-focused fine-mapping chip comprising 196 524 SNPs 
selected primarily based on genome wide association study [GWAS] 
analysis of 12 immune-mediated diseases.
2.1.2.2. Quality control
Quality control [QC] was performed using PLINKv1.07 software.15 
QC removed SNPs with a minor allele frequency [MAF] less than 
0.001, as well as SNPs with more than 10% missing genotypes. In 
total, 547 patients were selected [248 fibrostenotic CD patients and 
299 CD patients with purely inflammatory disease behaviour]. After 
removing duplicate individuals [n = 6] and individuals with more 
than 15% missing genotype data [n = 20], 521 individuals remained 
[no differential missingness, χ2 p = 0.67]. After QC, the dataset con-
sisted of 521 individuals and 166 251 SNPs with a genotyping call 
rate of 99%.
2.1.2.3. Statistical analysis and prioritization of SNPs for 
replication
After allele association analysis [χ2 test] and cluster plot inspection, 
34 SNPs with a p-value < 1.0 × 10–3 remained. To adequately test 
each locus for association in the replication phase we selected two 
SNPs per locus where possible. In addition, we decided to test the 
SNP that previously showed the strongest association with severe 
CD disease course [rs12212067, FOXO3], although this SNP was 
not associated with fibrostenotic disease in our discovery cohort.10,16 
In total, 43 SNPs passed the design of two plexes with the Assay 




Forty-three SNPs were genotyped using the Agena Bioscience 
Massarray in the replication phase [http://agenabio.com]. During 
QC we excluded SNPs with a Hardy–Weinberg equilibrium 
p-value  <  0.0001 in controls and an overall call rate <  90% and 
individuals with < 85% of SNPs confidently genotyped. After QC, 
the replication cohort consisted of 80 CD cases with recurrent fibro-
stenotic disease behaviour, 340 CD patients with purely inflamma-
tory disease and 39 SNPs with a genotype call rate of 99%. Since 
rs11861007 failed the Agena Bioscience design and it was the 
only Immunochip SNP in the WWOX region, genotyping of SNP 
rs11861007 was performed using Taqman technology [Applied 
Biosystems].
2.1.3.2. Statistical analysis
Allelic association analysis [χ2 test] and meta-analysis of the com-
plete cohort was performed with PLINKv1.07 software.15 To test if 
disease localization could be a cofounding factor, we additionally 
performed an allelic association analysis for rs11861007 [χ2 test] 
in ileal disease patients [n = 86] vs colonic disease patients [n = 36]. 
Similarly, allelic association analysis for rs11861007 [χ2 test] in 
Montreal Class B2 phenotype patients [n = 165] vs Montreal Class 
B1 and B3 phenotype patients [776] was performed to determine 
whether rs11861007 was associated with the Montreal B2 pheno-
type [and not recurrent fibrostenotic disease]. Logistic regression 
analyses with disease as a covariate was performed with R statistics.
Given that the prevalence of recurrent stenotic disease in CD 
was 0.04 in our replication cohort, that the allele frequency of our 
rs11861007 risk allele A  is 0.06 in Caucasian patients of Western 
and Central European descent  (CEU), and that we expected the 
risk variant to have an odds ratio [OR] of 4.3, we expected to have 
> 80% power to discover this association in our replication cohort. 
Ultimately, we only had 60% power to detect the association that we 
did detect for rs11861007 in our replication cohort at an OR of 2.1 
[http://zzz.bwh.harvard.edu/gpc/cc2.html].
2.2.2. SNP annotation
LocusZoom was used to construct regional association plots17 
[Supplementary Figure S1]. Exploration of the linkage disequilibrium 
[r2  >  0.8] was performed with Haploview.18 We assessed whether 
associated SNPs had known functional consequences or regulatory 
features. The Encyclopedia of DNA Elements [ENCODE]19 was 
searched using the UCSC Genome Browser.20 Specifically, SNPs 
located in the following regulatory features were searched: DNaseI-
hypersensitivity sites, transcription factor binding sites, histone mod-
ification and DNA-polymerase sites. We tested whether associated 
variants [or SNPs in high linkage disequilibrium [r2 > 0.8]] showed 
an effect on gene expression levels of genes. Expression quantitative 
trait loci [eQTL] analysis was performed with the eQTL browser 
[http://genenetwork.nl/bloodeqtlbrowser/], based on non-trans-
formed peripheral blood in 5311 individuals.21 Additional enhancer 
analyses were performed with the Fantom5 enhancer atlas.22
2.2.3. In silico analysis [rs11861007]
The strongest association for fibrostenotic disease was found in the 
RP11-679B19.1 lncRNA, and in the WWOX gene. The function 
of the RP11-679B19.1 lncRNA is unknown. To predict in which 
biological or cellular process and molecular function the WWOX 
gene is involved, we used an in-house developed RNA network tool 
[http://www.genenetwork.nl].23 The RNA network uses a method, 
based on principal component analysis, to build transcriptional 
profiles for biological pathways, which can be used to predict gene 
functions. A more detailed description of the method of the RNA 
network can be found in the paper by Fehrmann et al.23
2.4. Expression analysis
2.4.1. Resection material of CD patients
2.4.1.1. Subjects
The resection material was collected during surgical resection pro-
cedures [samples of the small bowel and colon] from patients for 
whom we had extensive phenotype data [University Medical Center 
Groningen]. Twenty-nine patients with fibrostenotic CD behaviour 
were included. The resection material of CD patients was preserved 
[storage at −80°C] in three parts: the ileum [proximal of the ste-
nosis], the stenosis itself [medial part] and the colon [distal of the 
stenosis]. As stenotic tissue is a final stage in the process of fibro-
sis formation, we considered the stenotic tissue, medial part of the 
resection, as not representative. Therefore, we included only samples 
of the ileum and colon, respectively proximal and distal from the 
stenosis. Pathology records of the resection material were checked 
and revealed no severe inflammation or fibrosis at the end of the 
resection sides, proximal and distal, of the stenosis.
2.4.1.2. Genotyping and patient selection
After DNA isolation, genotyping of the WWOX SNP [rs11861007] 
in 71 patients was performed using Taqman technology with a call 
rate of 96% [Life Technologies]. We selected the five CD patients 
who carried the WWOX-genotype [risk allele, A] as cases [we 
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found no patients homozygous for the risk allele in our cohort]. We 
selected five matched CD patients with the GG genotype [wild-type] 
as controls [matched based on age, disease duration, inflammation 
and stenosis].
Quantitative polymerase chain reaction [qPCR] was performed 
of WWOX, TGF-β, iNOS, IL1-B, TNF-α, FOXP3, α-SMA, Collagen 
Type 1 and downstream genes PAI-I [SERPINE] and CTGF of the 
ileocolonic tissue of five CD patients carrying the WWOX risk allele 
and five CD patients homozygous for the WWOX wild-type allele 
[see Online Methods].
3. Results
In this study we included two independent case-control cohorts 
totalling 322 recurrent fibrostenotic and 619 purely inflammatory 
CD cases; 60% of the cohort were female with a mean age at diag-
nosis of 25  years. The cohorts were selected based on ‘extreme 
phenotypes’, resulting in a statistically significant difference in 
disease location and behaviour between patients [Table 1]. After 
analysis of 166 251 SNPs in 242 fibrostenotic and 279 purely 
inflammatory CD cases and replication of 34 selected SNPs in an 
independent cohort of 80 fibrostenotic and 340 purely inflamma-
tory CD cases, the combined meta-analysis resulted in a genome-
wide significant signal for SNP rs11861007 [p  =  6.09  ×  10–11, 
OR  =  3.2, heterogeneity [I2]  <  75%] [Table  2, Supplementary 
Table S1]. The minor heterogeneity for SNP rs11861007 between 
the discovery and the replication cohort might be caused by a 
slight admixture of non-cases and/or non-controls in the rep-
lication cohort, as described in the Methods section. To assess 
whether the association between rs11861007 and fibrosten-
otic disease was not mainly due to ileal disease localization we 
tested this marker for association with ileal disease localization. 
We found no association between rs11861007 and ileal disease 
localization [p = 0.27]. Additional logistic regression analyses for 
the association between SNP rs11861007 and re-fibrosis, with 
disease location as a covariate, still showed a significant asso-
ciation [p  =  0.004]. We also tested for an association between 
rs11861007 and the Montreal Class B2 phenotype [any stricuring 
disease] in our cohort, but did not find an association [p = 0.25].
3.1. SNP annotation and in silico analyses
rs11861007 is located on chromosome 16, in an intron close to exon 
9 of the WWOX gene, which codes for WW domain-containing 
oxidoreductase. Neither rs11861007 nor SNPs in high linkage dis-
equilibrium [r2 > 0.8] have known functional or regulatory features 
[eQTL or regulatory elements assessed in the ENCODE Encyclopedia 
of DNA Elements or FANTOM5 enhancers].22 WWOX is the only 
coding gene in the locus [defined as 250 kb on either side of our top 
hit] making it the most likely positional candidate gene. The SNP is 
also located in the lncRNA RP11-679B19.1, in which it might affect 
folding, but for this lnRNA there is also no eQTL effect, and no 
function is known for RP11-679B19.1.
Co-transcriptional pathway analysis using an in-house-developed 
RNA network tool23 predicts WWOX involvement with cellular com-
ponents in the extracellular matrix compartment [p = 1.41 × 10–3] 
and an association with collagen binding [p  =  9.78  ×  10–5]. See 
Supplementary Table S2 for involvement in other pathways.
3.2. Expression analyses
Normal ileal and colonic tissue residing proximal to and distal from 
the stenotic part was sampled from five CD patients heterozygous 
for the WWOX risk allele [A] and five CD patients homozygous for 
the WWOX wild-type allele [G]. WWOX mRNA levels were similar 
in both the ileal and the colonic tissue of patients with or without the 
risk allele [Supplementary Figure S2]. In contrast, TGF-β expression 
was significantly higher in the colonic tissue of risk-allele-carrying 
patients compared to patients homozygous for the wild-type allele 
[Mann–Whitney U-test, p = 0.0079] [Figure 1A]. Similarly, down-
stream targets involved in fibrosis, such as Connective Tissue Growth 
Factor [CTGF] and matricellular PAI-1 [SERPINE1], showed a 
trend towards increased expression in the risk-allele-carrying CD 
patients compared to the patients homozygous for the wild-type 
allele [Figure 1B; see Supplementary Figure S2 for all qPCR results].
4. Discussion
In this study, we have identified a variant in the WWOX gene as a 
disease-modifier associated with a recurrent fibrostenotic phenotype 
in CD, and we have replicated this association in an independent 
Table 1. Clinical characteristics of patients in the combined cohort
Fibrostenotic CD Purely inflammatory CD p-value
n [%] 322 [100%] 619 [100%]
Patient characteristics
Female, n [%] 180 [56%] 371 [60%] 0.23
Median age of onset, years [IQR 25–75] 24 [18–30] 26 [19–36] 0.38
Disease location, n [%]
Montreal-L1, ileal 86 [27%] 93 [15%] 0.06
Montreal-L2, colonic 36 [11%] 291 [47%] <0.0001
Montreal-L3 ileocolonic 200 [62%] 235 [38%] 0.0011
Montreal-L4, additional upper disease localization 32 [10%] 55 [9%] 1
Disease behaviour, n [%]
Montreal-B1, inflammatory 0 619 [100%]
Montreal-B2, stricturing 165 [51%] 0
Montreal-B3, penetrating 157 [49%] 0
Time until surgery
Disease duration in years from diagnosis until first surgery, mean [SD] 4.1 [6.5]
This table provides the clinical characteristics of patients with recurrent fibrostenotic and purely inflammatory CD in the combined cohort. Disease location and 
behaviour is based on the Montreal classification for CD. Chi-squared and Mann-Whitney U-tests [only for age of onset] are used to calculate the p-value. CD, 
Crohn’s disease; IQR, interquartile range.
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cohort. We found that patients carrying the risk allele show enhanced 
profibrotic signalling, through higher expression of tumour growth 
factor-β [TGF-β], in the colon. This suggests that the genetic vari-
ant in WWOX is associated with a decrease of WWOX function. 
Alternatively, the effect could be caused by a configuration change of 
the lnRNA RP11-679B19.1, which has recently been recorded in the 
same locus and is, yet, of unknown function.
The genetic variants that contribute to disease behaviour can 
be different from the variants that contribute to disease susceptibil-
ity. This has been shown for a variant affecting FOXO3A expres-
sion, which was found to be significantly associated with disease 
prognosis but which was not associated with CD susceptibility.16 In 
this study, we confirm the concept that disease-modifying genes can 
differ from variants contributing to disease development. The SNP 
found to be most closely associated [rs11861007] has not been asso-
ciated with disease development in previous studies.4 Previous geno-
type–phenotype studies in IBD patients have not studied the specific 
phenotype in the present study: recurring ileal fibrostenosis in CD.6 
Previous studies focusing on genetic variants associated with a single 
fibrotic event in CD found associations with variants in SMAD3 and 
MAGI, but due to the diverse coverage of the genotyping platforms 
we could not replicate these findings.7,8 We could also not confirm a 
previously described association between NOD2 variants and ileal 
fibrostenotic disease, which might be due to the fact that we studied 
recurrent fibrostenosis, not necessarily ileal, or because the NOD2 
variants are relatively rare in our cohort.
The SNP [rs11861007] is located in an intron close to exon 9 
of the WWOX gene. Although we could not find an eQTL effect, 
regulatory features or enhancer activity, the WWOX gene is the only 
coding gene in the locus [defined as 250 kb on either side of our top 
hit] making it the most likely positional candidate gene. The SNP 
is also located in the lncRNA RP11-679B19.1, in which it might 
affect folding, but for this lnRNA there is also no eQTL effect, and 
no function is known for RP11-679B19.1. WWOX is a known 
tumour suppressor gene and encodes a protein that contains two 
WW domains and a short-chain dehydrogenase/reductase domain 
[SRD]. The mechanism of tumour suppression of WWOX involves 
apoptosis, modulation of the extracellular matrix and modulation 
of cell bioenergetics24 Genome-wide association studies have shown 
that WWOX also plays a role in the pathogenesis of pulmonary 
fibrosis.25 Targeted deletion of Wwox  in epithelium in the mam-
mary gland increased fibronectin levels24 and conditional deletion of 
Wwox in the mammary gland significantly upregulated multiple col-
lagen genes.26 Moreover, molecular functions predicted by our RNA 
network tool show that WWOX plays a role in fibrosis formation, in 
agreement with the previously described literature reports.
The main mediator between intestinal inflammation and fibrosis 
in IBD is TGF-β,27 which is overexpressed in intestinal tissue in CD 
patients.28 Upon TGF-β stimulation, WWOX acts as an inhibitor of 
SMAD3 transcriptional activity by sequestering it in the cytoplasm.29 
We show an enhanced TGF-β expression in CD patients carrying 
the WWOX risk allele. TGF-β stimulates downstream signalling 
pathways resulting in expression of several profibrotic genes, includ-
ing CTGF. qPCR analysis of CTGF in this study showed a trend 
towards increased expression in the WWOX risk-allele-carrying CD 
patients compared to the patients homozygous for the WWOX wild-
type allele. We conclude that WWOX risk-allele-carrying individu-
als have enhanced TGF-β expression with a trend towards elevated 
expression of profibrotic genes as a downstream effect.
There are some limitations to this study. First, the cohort size is 
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‘extreme phenotypes’ we increased the power of our analysis. This 
approach provides power to detect associations within disease 
cohorts and the approach has been successfully adopted for other 
traits.11,12 Moreover, we replicated our findings in an independent 
cohort. Second, the upregulation of TGF-β in the ileal part of the 
resection material [upstream of the stenosis] in patients carrying 
the WWOX risk allele was a trend and not statistically signifi-
cant. However, in the colonic part of the resection material [down-
stream of the stenosis] in patients carrying the WWOX risk allele 
we do show statistically significant enhanced TGF-β expression. All 
available WWOX risk-allele-carrying patients in our centre were 
included, but because the risk allele has a low frequency this num-
ber is quite small, which means our study is relatively underpow-
ered. Increasing the sample size may turn the trend we observe into 
a significant association. Finally, the WWOX–SMAD3–TGF-β path-
way has been described previously29 and it has been proven that the 
proteins encoded by the genes interact, although the exact pathways 
through which they interact have not yet been elucidated, making it 
difficult to interpret the results from our study.
In conclusion, we have identified and replicated WWOX as a 
disease-modifying gene associated with the recurrent fibrostenotic 
phenotype in CD. Our expression analyses suggest a functional effect 
of the risk allele through enhanced expression of TGF-β in risk-allele 
carriers, indicating profibrotic expression. CD patients carrying the 
WWOX risk allele appear to have a profibrotic profile. To avoid 
fibrotic complications, it might be advisable to refrain from prescrib-
ing anti-inflammatory medication that enhances TGF-β signalling in 
intestinal fibroblasts in these patients.
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the risk allele [AG] and five CD patients homozygous for the wild-type allele [GG]. CD, Crohn’s disease; qPCR, quantification polymerase chain reaction; TGF-β, 
transforming growth factor; CTGF, connective tissue growth factor; homozyg, homozygous; heterozyg, heterozygous.
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